Beijing-based Surgerii Robotics has closed a $100 million Series D led by Shanghai private-equity group Loyal Valley Capital, the company said in a LinkedIn post the company referenced in early-year disclosures. The financing is earmarked for global commercialization and clinical adoption of SHURUI, the company's single-port endoscopic surgical robot, and for next-generation product development.
Single-Port System Hits Global Scale
SHURUI is cleared for urologic, gynecologic, general and thoracoscopic procedures in both adult and pediatric patients, and uses multi-directional instrument articulation through a single incision designed to reduce surgical trauma and speed recovery. The system launched commercially in China in late 2024 and has now been used in more than 3,000 human surgeries domestically. In August 2025 the system received Europe's CE mark, and Surgerii has reported collaboration with more than 70 hospitals in China and nearly 10 in Europe.
European Footprint Through IRCAD Partnership
To prepare European surgeons, Surgerii set up a dedicated training center last year at France's IRCAD, the same surgical-education institute Medtronic partnered with through its North American arm to support Hugo. The Europe-Asia talent pipeline is a deliberate hedge against the regulatory and reimbursement complexity that has tripped up earlier robotic-surgery entrants.
A Crowded, Hardening Single-Port Market
Surgerii's raise lands in a robotic-surgery market that has gone from a near-monopoly to a multi-system race in 18 months. Intuitive Surgical's da Vinci SP single-port system gained new U.S. indications in December 2025 for inguinal-hernia repair, gallbladder removal and appendectomy, and Medtronic's Hugo soft-tissue robot won FDA clearance the same month. CMR Surgical began its U.S. roll-out of Versius Plus for cholecystectomy this month, while Johnson & Johnson is awaiting FDA action on its OTTAVA platform. Virtual Incision continues to push a next-generation version of its MIRA miniaturized robot after a 2024 de novo clearance.
Investor Syndicate And Use Of Proceeds
In addition to lead investor Loyal Valley Capital, Shanghai Healthcare Capital, V Star Capital, DNV Capital and Hefei Industrial Investment joined the round. The proceeds will go toward scaling commercial operations outside China, building out Surgerii's training and service network, and developing next-generation instruments and visualization features for SHURUI.
Reporting based on coverage from MedTech Dive, The Robot Report and Surgical Robotics Technology.